A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
A legfontosabb adatok
- Ki végzi
- BeiGene
- Hol
- Kína6 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Fut, nem toboroz
- Fázis
- 4. fázis
- Résztvevők
- 16 fő vett részt
- Kezdés
- 2025. okt. 17.
- Várható befejezés
- 2028. okt. 31.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Zanubrutinib
- A regiszteradat frissítve
- 2026. augusztus 10.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 14 feltétel megnézéseKevesebb
Ki vehet részt
- Clinical and definitive histologic diagnosis of WM. Participant must be treatment-naive
- Participant must meet at least 1 criterion for treatment according to consensus panel criteria from the Seventh International Workshop on Waldenström's macroglobulinemia (IWWM)
- Participant must have measurable disease, as defined by serum immunoglobulin M (IgM) level > 0.5 g/dL
- Participants must have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
- Participants must have adequate organ function as indicated by the following laboratory values ≤ 7 days before the first dose of study treatment:; Participants must not have required blood transfusion or growth factor support ≤ 7 days before sample collection at screening for the following:; Absolute neutrophil count (ANC) ≥ 0.75 x 10\^9/L; Platelets ≥ 50 x 10\^9/L; Creatinine clearance of ≥ 30 ml/min as estimated by the Cockcroft-Gault formula; Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN); Serum total bilirubin ≤ 2 x ULN (total bilirubin must be < 3 x ULN for participants with Gilbert syndrome)
- Female participants of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for at least 1 month after the last dose of zanubrutinib. They must also have a negative urine or serum pregnancy test result ≤ 7 days before the first dose of study treatment
Ki nem vehet részt
- Central nervous system (CNS) involvement by WM. Patients with a history of CNS involvement must undergo magnetic resonance imaging (MRI) and cerebrospinal fluid cytology studies to document no evidence of CNS disease prior to study entry
- Participants with any of the following cardiovascular risk factors:; Active cardiac ischemia (eg, cardiac chest pain) ≤ 28 days before first dose of study drug; Any history of acute myocardial infarction ≤ 6 months before the first dose of study drug; Any history of heart failure meeting New York Heart Association (NYHA) Classification III or IV (Appendix 7)≤ 6 months before the first dose of study drug; Any event of ventricular arrhythmia ≥ Grade 2 in severity ≤ 6 months before the first dose of study drug; Active, clinically significant second-degree atrioventricular block Mobitz II, or third degree atrioventricular block; Any history of cerebrovascular accident ≤ 6 months before the first dose of study drug; Uncontrolled hypertension that cannot be managed by standard antihypertension medications ≤ 28 days before the first dose of study drug; Any episode of syncope or seizure ≤ 28 days before first dose of study drug
- Participants requiring ongoing therapy with strong or moderate cytochrome CYP3A inducers
- Corticosteroids given with antineoplastic intent within 7 days, or chemotherapy, targeted therapy, or radiation therapy within 4 weeks, or antibody-based therapy within 4 weeks before the start of study drug
- Major surgical procedure within 4 weeks before the start of study treatment (bone marrow aspirate and biopsy procedures are not considered major surgical procedures); Note: Other protocol defined criteria may apply
- Evidence of disease transformation at the time of study entry
- Evidence of disease transformation at the time of study entry
- At the time of study entry, participants taking warfarin or other vitamin K antagonists
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to measure the efficacy and safety with zanubrutinib in adults with Treatment-Naive (TN) Waldenström Macroglobulinemia (WM). The main objective of this Phase 4 study is to further characterize the efficacy of zanubrutinib in Chinese participants with TN WM in order to fulfill the post-marketing requirements from the National Medical Products Administration (NMPA). Safety data will be collected and evaluated in this study as well.
A vizsgálat csoportja
- ZanubrutinibA vizsgált kezelés
Participants will receive 160 mg zanubrutinib orally twice a day until progressive disease, unacceptable toxicity or death, withdrawal of consent, loss to follow-up, or study termination by the sponsor for any reason.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 4, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Patients With Treatment-Naive Waldenström Macroglobulinemia
- A regiszteradat frissítve
- 2026. augusztus 10.